Description: Modus Therapeutics Holding AB (publ), a biotechnology company, develops a treatment for sepsis and septic shock in Sweden. Its lead product is Sevuparin, a polysaccharide to treat patients with sepsis and septic shock, which is under Phase Ib clinical study. The company was founded in 2011 and is headquartered in Stockholm, Sweden.
Home Page: www.modustx.com
Olof Palmes gata 29 IV
Stockholm,
11122
Sweden
Phone:
46 8 50 13 70 00
Officers
| Name | Title |
|---|---|
| Dr. John Öhd M.D., Ph.D. | Chief Exec. Officer |
| Mr. Claes Lindblad | Chief Financial Officer |
Exchange: ST
Country: SE
Currency: Swedish krone (kr)
| Forward PE: | 0 |
|---|---|
| Trailing PE: | 0 |
| Price-to-Book MRQ: | 5.778 |
| Price-to-Sales TTM: | 0 |
| IPO Date: | |
| Fiscal Year End: | December |
| Full Time Employees: | 2 |